Battle for Barne: Ep2 – Secret phones, wiped laptops and ‘dirty' money
Mr Magnier, the bloodstock billionaire, and two of his children are seeking to enforce a handshake deal agreed between Mr Magnier and Richard Thomson-Moore to buy Barne Estate, a 751-acre property in Tipperary that has been in the Thomson-Moore family for nearly 400 years.
Mr Magnier contends that the €15m deal agreed in his Coolmore home in Tipperary on August 22, 2023 with Mr Thomson-Moore is binding.
He argues that a later €22.5m deal Mr Thomson-Moore and his family trust agreed with Maurice Regan, the US-based Kerry building tycoon, is 'unlawful'.
Land, riches and reputations are all on the line, with recent evidence hearing details of secret phones, wiped computers, hidden assets and 'dirty' money.
Today on The Indo Daily, in the second of a two-part special, Fionnán Sheahan is joined by Mark Tighe, journalist with the Sunday Independent, to hear the blockbuster revelations in the case over the future of Barne estate.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
an hour ago
- Irish Times
AstraZeneca's potential exit raises alarm for UK markets
AstraZeneca chief executive Pascal Soriot isn't confirming or denying reports that the UK's largest listed company is considering moving its primary stock market listing from London to New York. Yet recent remarks reveal where the company's future may lie. At AstraZeneca's half-year results press conference, Soriot gushed about the US, 'the country in our industry where innovation is taking place'. AstraZeneca is 'a very American company'. Soriot 'always believed in the great future of America' and, just to be sure no one missed the message, added: 'I definitely love America.' It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in Virginia, and expects half its sales to come from the US by 2030. READ MORE While reaffirming its commitment to UK research sites such as Cambridge, Soriot stopped short of endorsing the London listing. His critique of Europe's low pharmaceutical investment and NHS pricing controls hints at wider tensions. The UK market has seen multiple major departures: CRH, Flutter, Arm and BHP. Pharmaceutical company Indivior left in July. Payment firm Wise is also saying farewell. In the past year 88 companies left the UK market, with another 70 already exiting in 2025, seeking higher valuations and liquidity in the US. AstraZeneca's exit would deal the biggest blow yet to the London Stock Exchange, so expect renewed calls for tax reform – especially 0.5 per cent stamp duty on shares – and regulatory easing. Otherwise, the argument goes, the Square Mile risks losing more ground to Wall Street.
Irish Times
2 hours ago
- Irish Times
Is Trump's tariff plan working or is this the quiet before the storm?
Donald Trump and his economic advisers are said to feel vindicated. Bilateral trade deals are rolling in and, in the main, on more favourable terms for the US . Tariff revenue is soaring. Financial markets are fluctuating near record highs and predictions that inflation would soar have not yet materialised. Is this the quiet before the storm or is Trump's tariff plan, which nearly every mainstream economist says is destined to fail, succeeding? In truth no one knows but every data point is being picked over for clues. READ MORE The latest job figures from the US for July were weak and contained downward revisions from a previously announced levels, suggesting companies might 'already been pre-emptively slowing their hiring amid the uncertainty created by months of tariff threats and pauses from the White House', according to one report. US inflation, meanwhile, accelerated to 2.7 per cent in June without a commensurate increase in consumer spending, suggesting higher import prices from tariffs maybe fuelling prices. Federal Reserve chairman Jerome Powell has so far resisted lowering interest rates like the European Central Bank because of the US's strong labour market and the upside risks to inflation from tariffs, much to Trump's annoyance. Though concerning, the economic data don't exactly point to a big pivot in underlying performance and aren't likely to spook the White House just yet. But they do represent turbulence and remember much of the tariff impact has yet to play out. [ US tariffs will mean 70,000 fewer jobs created in Irish economy, Department of Finance warns Opens in new window ] There's a lag time before higher prices get passed on to businesses and consumers because of front-loading and other dynamics. Trump's first term in office did feature tariff threats but ones that met resistance from within the White House and which were eventually moderated. This time, it's different. Easy wins in trade negotiations with Britain, Europe and Japan has emboldened the president. Explaining the EU's quick capitulation, one insider said Germany, after enduring a gruelling energy price shock, 'wanted stability and didn't care what the price'. The average effective tariff rate on US imports is now at its highest level in nearly a century. Will it send the US economy into reverse or will Trump and Maga operatives muddle through?
RTÉ News
a day ago
- RTÉ News
Trump claims victory on trade - but EU had little choice
In many respects US President Donald Trump achieved his aims by introducing a swath of tariffs with America's main trading partners around the world. The European Union has a population of 448 million compared to the US which has 340 million. However, the US economy is larger. Many have been surprised at the way Donald Trump has appeared to be able to dictate terms to Europe. His announcement yesterday that he would commence the new tariff arrangements from 7 August appeared to be his decision with little input from the EU. President of the European Commission Ursula Von Der Leyen has defended the deal, which will see tariffs of 15% imposed on EU goods. There are two reasons why the EU did not want a full blown trade war with Mr Trump. Firstly, European businesses were opposed to a prolonged period of tit-for-tat tariffs with enormously damaging consequences. Secondly, if relations with Mr Trump soured, he could threaten to row back on defence commitments. The EU is highly reliant on the US for arm supplies, funding for NATO and military support for Ukraine. But looking at scale of tariffs imposed on other countries the EU's 15% does not seem too damaging compared to India's 25%, Canada's 35% and Switzerland's 39%. Most of the US' main trading partners have rates of 15% or 20%. The exception is the UK's 10% tariff. However, this is not an all-inclusive rate. In other words, other rates can be added to it. Nor does Britain have a written agreement capping pharmaceutical tariffs unlike the EU. It is worth bearing in mind that while tariffs on European goods go up, Mr Trump stated the EU would be "opening up their countries at zero tariffs" for US exports. Unanswered questions From the Irish point of view there are still many unanswered questions. There is no agreement on alcohol exports to the US. That sector was expected to be covered by a zero-for-zero tariff arrangement but that has not yet been confirmed. This is critical for Ireland's whiskey industry and the EU's wine exports. It seems clear that pharmaceuticals and computer chips will face tariffs of up to 15%, but the timing is still uncertain. Both are subject of so-called Section 232 investigations because Mr Trump believes the US' use of imports is a national security issue. Tánaiste Simon Harris said the tariffs for sectors under investigation will not become clear until those processes are concluded. For pharmaceuticals that is expected to happen in two weeks. But the fact that the EU-US agreement won't exceed 15% does provide some clarity for the industry. Bank of Ireland pointed out that drugs are relatively inelastic, which means if prices go up people still buy them because they are prescribed by doctors. The new swath of tariffs come at a time when the dollar has been weakening and making EU exports to the US more expensive at the worst possible time. Then there is the question of what this all means for the Irish economy. In March, the Department of Finance and the Economic Social Research Institute published research on the impact of tariffs on the Irish economy. It looks at a range of scenarios from tariffs of 10% to 25%. Based on that analysis, officials at the Department of Finance told business leaders yesterday that the economy would continue to expand, but at a slower pace than previously expected. Employment will grow but at a slower rate. The Government will now have to decide how all this will impact the Budget in October. But while Mr Trump may believe he has achieved his aims on tariffs, in the long run his actions carry the risk of higher inflation in the US and undermining the American economy.
